KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Abbott Laboratories (ABT) Leases (2019 - 2025)

Abbott Laboratories' Leases history spans 7 years, with the latest figure at $1.1 billion for Q4 2025.

  • For Q4 2025, Leases rose 4.74% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $1.1 billion, up 4.74%, while the annual FY2025 figure was $1.1 billion, 4.74% up from the prior year.
  • Leases for Q4 2025 was $1.1 billion at Abbott Laboratories, up from $1.1 billion in the prior quarter.
  • Across five years, Leases topped out at $1.2 billion in Q4 2021 and bottomed at $1.1 billion in Q4 2024.
  • The 5-year median for Leases is $1.1 billion (2023), against an average of $1.1 billion.
  • The largest annual shift saw Leases dropped 4.19% in 2024 before it increased 4.74% in 2025.
  • A 5-year view of Leases shows it stood at $1.2 billion in 2021, then fell by 3.21% to $1.1 billion in 2022, then increased by 0.54% to $1.1 billion in 2023, then dropped by 4.19% to $1.1 billion in 2024, then rose by 4.74% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Leases are $1.1 billion (Q4 2025), $1.1 billion (Q4 2024), and $1.1 billion (Q4 2023).